Search

Your search keyword '"Mangala, Lingegowda S."' showing total 557 results
Start Over Author "Mangala, Lingegowda S."
557 results on '"Mangala, Lingegowda S."'

1. Overcoming adaptive resistance to anti-VEGF therapy by targeting CD5L

Author

LaFargue, Christopher J., Amero, Paola, Noh, Kyunghee, Mangala, Lingegowda S., Wen, Yunfei, Bayraktar, Emine, Umamaheswaran, Sujanitha, Stur, Elaine, Dasari, Santosh K., Ivan, Cristina, Pradeep, Sunila, Yoo, Wonbeak, Lu, Chunhua, Jennings, Nicholas B., Vathipadiekal, Vinod, Hu, Wei, Chelariu-Raicu, Anca, Ku, Zhiqiang, Deng, Hui, Xiong, Wei, Choi, Hyun-Jin, Hu, Min, Kiyama, Takae, Mao, Chai-An, Ali-Fehmi, Rouba, Birrer, Michael J., Liu, Jinsong, Zhang, Ningyan, Lopez-Berestein, Gabriel, de Franciscis, Vittorio, An, Zhiqiang, and Sood, Anil K.

Published
2023
Full Text
View/download PDF

2. Molecular Analysis of Short- versus Long-Term Survivors of High-Grade Serous Ovarian Carcinoma

Author

Stur, Elaine, Bayraktar, Emine, Dal Molin, Graziela Zibetti, Wu, Sherry Y, Mangala, Lingegowda S, Yao, Hui, Wang, Ying, Ram, Prahlad T, Corvigno, Sara, Chen, Hu, Liang, Han, Tworoger, Shelley S, Levine, Douglas A, Lutgendorf, Susan K, Liu, Jinsong, Moore, Kathleen N, Baggerly, Keith A, Karlan, Beth Y, and Sood, Anil K

Subjects
Cancer, Ovarian Cancer, Genetics, Biotechnology, Rare Diseases, long-term survival, short-term survival, ovarian cancer, HGSC, TMEM62, Oncology and Carcinogenesis
Abstract

Despite having similar histologic features, patients with high-grade serous ovarian carcinoma (HGSC) often experience highly variable outcomes. The underlying determinants for long-term survival (LTS, ≥10 years) versus short-term survival (STS, 2; false discovery rate < 0.01). In the subsequent validation cohort, transmembrane protein 62 (TMEM62) was found to be related to LTS. CIBERSORT analysis showed that T cells (follicular helper) were found at higher levels in tumors from LTS than STS groups. In vitro data using OVCAR5 and OVCAR8 cells showed decreased proliferation with TMEM62 overexpression and positive correlation with a longevity-regulating pathway (KEGG HSA04213) at the RNA level. In vivo analysis using the OVCAR8-TMEM62-TetON model showed decreased tumor burden in mice with high- vs. low-expressing TMEM62 tumors. Our results demonstrate that restoring TMEM62 may be a novel approach for treatment of HGSC. These findings may have implications for biomarker and intervention strategies to help improve patient outcomes

Published
2022

3. Enhancing oral delivery of plant-derived vesicles for colitis

Author

Liu, Yuan, Ahumada, Adrian Lankenau, Bayraktar, Emine, Schwartz, Paul, Chowdhury, Mamur, Shi, Sixiang, Sebastian, Manu M., Khant, Htet, de Val, Natalia, Bayram, Nazende Nur, Zhang, Guodong, Vu, Thanh Chung, Jie, Zuliang, Jennings, Nicholas B., Rodriguez-Aguayo, Cristian, Swain, Jody, Stur, Elaine, Mangala, Lingegowda S., Wu, Yutuan, Nagaraju, Supriya, Ermias, Brooke, Li, Chun, Lopez-Berestein, Gabriel, Braam, Janet, and Sood, Anil K.

Published
2023
Full Text
View/download PDF

4. Activating p53 family member TAp63: A novel therapeutic strategy for targeting p53‐altered tumors

Author

Gunaratne, Preethi H, Pan, Yinghong, Rao, Abhi K, Lin, Chunru, Hernandez‐Herrera, Anadulce, Liang, Ke, Rait, Antonina S, Venkatanarayan, Avinashnarayan, Benham, Ashley L, Rubab, Farwah, Kim, Sang Soo, Rajapakshe, Kimal, Chan, Clara K, Mangala, Lingegowda S, Lopez‐Berestein, Gabriel, Sood, Anil K, Rowat, Amy C, Coarfa, Cristian, Pirollo, Kathleen F, Flores, Elsa R, and Chang, Esther H

Subjects
Ovarian Cancer, Lymphoma, Hematology, Rare Diseases, Biotechnology, Cancer, Genetics, Orphan Drug, Aetiology, 2.1 Biological and endogenous factors, Animals, Antineoplastic Agents, Binding Sites, Cell Line, Tumor, Cell Movement, Cisplatin, Drug Resistance, Neoplasm, Female, Humans, Liposomes, Mice, Mice, Nude, MicroRNAs, Mutation, Missense, Neoplasm Invasiveness, Ovarian Neoplasms, Protein Isoforms, Signal Transduction, Transcription Factors, Transcriptional Activation, Transfection, Tumor Suppressor Protein p53, Tumor Suppressor Proteins, Xenograft Model Antitumor Assays, 3-dimensional (3D) spheroids, B-cell lymphoma 2-like protein 11, chemosensitization, cisplatin, leoyl-sn-glycero-3-phosphatidylcholine, microRNA 130b, ovarian cancer, transactivation (TA) and N-terminally truncated (Delta N) isoforms of the p63 protein (TAp63, Delta Np63), tumor protein p53, tumor-targeted nanocomplex, transactivation (TA) and N-terminally truncated (ΔN) isoforms of the p63 protein, Oncology and Carcinogenesis, Public Health and Health Services, Oncology & Carcinogenesis
Abstract

BackgroundOver 96% of high-grade ovarian carcinomas and 50% of all cancers are characterized by alterations in the p53 gene. Therapeutic strategies to restore and/or reactivate the p53 pathway have been challenging. By contrast, p63, which shares many of the downstream targets and functions of p53, is rarely mutated in cancer.MethodsA novel strategy is presented for circumventing alterations in p53 by inducing the tumor-suppressor isoform TAp63 (transactivation domain of tumor protein p63) through its direct downstream target, microRNA-130b (miR-130b), which is epigenetically silenced and/or downregulated in chemoresistant ovarian cancer.ResultsTreatment with miR-130b resulted in: 1) decreased migration/invasion in HEYA8 cells (p53 wild-type) and disruption of multicellular spheroids in OVCAR8 cells (p53-mutant) in vitro, 2) sensitization of HEYA8 and OVCAR8 cells to cisplatin (CDDP) in vitro and in vivo, and 3) transcriptional activation of TAp63 and the B-cell lymphoma (Bcl)-inhibitor B-cell lymphoma 2-like protein 11 (BIM). Overexpression of TAp63 was sufficient to decrease cell viability, suggesting that it is a critical downstream effector of miR-130b. In vivo, combined miR-130b plus CDDP exhibited greater therapeutic efficacy than miR-130b or CDDP alone. Mice that carried OVCAR8 xenograft tumors and were injected with miR-130b in 1,2-dioleoyl-sn-glycero-3-phosphatidylcholine (DOPC) liposomes had a significant decrease in tumor burden at rates similar to those observed in CDDP-treated mice, and 20% of DOPC-miR-130b plus CDDP-treated mice were living tumor free. Systemic injections of scL-miR-130b plus CDDP in a clinically tested, tumor-targeted nanocomplex (scL) improved survival in 60% and complete remissions in 40% of mice that carried HEYA8 xenografts.ConclusionsThe miR-130b/TAp63 axis is proposed as a new druggable pathway that has the potential to uncover broad-spectrum therapeutic options for the majority of p53-altered cancers.

Published
2019

6. Author Correction: Tuning microtubule dynamics to enhance cancer therapy by modulating FER-mediated CRMP2 phosphorylation

Author

Zheng, Yiyan, Sethi, Ritika, Mangala, Lingegowda S., Taylor, Charlotte, Goldsmith, Juliet, Wang, Ming, Masuda, Kenta, Carrami, Eli M., Mannion, David, Miranda, Fabrizio, Herrero-Gonzalez, Sandra, Hellner, Karin, Chen, Fiona, Alsaadi, Abdulkhaliq, Albukhari, Ashwag, Fotso, Donatien Chedom, Yau, Christopher, Jiang, Dahai, Pradeep, Sunila, Rodriguez-Aguayo, Cristian, Lopez-Berestein, Gabriel, Knapp, Stefan, Gray, Nathanael S., Campo, Leticia, Myers, Kevin A., Dhar, Sunanda, Ferguson, David, Bast, Jr, Robert C., Sood, Anil K., von Delft, Frank, and Ahmed, Ahmed Ashour

Published
2022
Full Text
View/download PDF

7. Platelets reduce anoikis and promote metastasis by activating YAP1 signaling.

Author

Haemmerle, Monika, Taylor, Morgan L, Gutschner, Tony, Pradeep, Sunila, Cho, Min Soon, Sheng, Jianting, Lyons, Yasmin M, Nagaraja, Archana S, Dood, Robert L, Wen, Yunfei, Mangala, Lingegowda S, Hansen, Jean M, Rupaimoole, Rajesha, Gharpure, Kshipra M, Rodriguez-Aguayo, Cristian, Yim, Sun Young, Lee, Ju-Seog, Ivan, Cristina, Hu, Wei, Lopez-Berestein, Gabriel, Wong, Stephen T, Karlan, Beth Y, Levine, Douglas A, Liu, Jinsong, Afshar-Kharghan, Vahid, and Sood, Anil K

Subjects
Blood Platelets, Cell Line, Tumor, Animals, Mice, Inbred C57BL, Humans, Mice, Nude, Ovarian Neoplasms, Neoplasm Metastasis, Adaptor Proteins, Signal Transducing, Phosphoproteins, Transplantation, Heterologous, Coculture Techniques, Gene Expression Profiling, Signal Transduction, Anoikis, RNA Interference, Female, Transcription Factors, Rare Diseases, Cancer, 2.1 Biological and endogenous factors, Cell Line, Tumor, Mice, Inbred C57BL, Nude, Adaptor Proteins, Signal Transducing, Transplantation, Heterologous
Abstract

Thrombocytosis is present in more than 30% of patients with solid malignancies and correlates with worsened patient survival. Tumor cell interaction with various cellular components of the tumor microenvironment including platelets is crucial for tumor growth and metastasis. Although it is known that platelets can infiltrate into tumor tissue, secrete pro-angiogenic and pro-tumorigenic factors and thereby increase tumor growth, the precise molecular interactions between platelets and metastatic cancer cells are not well understood. Here we demonstrate that platelets induce resistance to anoikis in vitro and are critical for metastasis in vivo. We further show that platelets activate RhoA-MYPT1-PP1-mediated YAP1 dephosphorylation and promote its nuclear translocation which induces a pro-survival gene expression signature and inhibits apoptosis. Reduction of YAP1 in cancer cells in vivo protects against thrombocytosis-induced increase in metastasis. Collectively, our results indicate that cancer cells depend on platelets to avoid anoikis and succeed in the metastatic process.Platelets have been associated with increased tumor growth and metastasis but the mechanistic details of this interaction are still unclear. Here the authors show that platelets improve anoikis resistance of cancer cells and increase metastasis by activating Yap through a RhoA/MYPT-PP1 pathway.

Published
2017

9. EphA2- and HDAC-Targeted Combination Therapy in Endometrial Cancer

Author

Joseph, Robiya, primary, Dasari, Santosh K., additional, Umamaheswaran, Sujanitha, additional, Mangala, Lingegowda S., additional, Bayraktar, Emine, additional, Rodriguez-Aguayo, Cristian, additional, Wu, Yutuan, additional, Nguyen, Nghi, additional, Powell, Reid T., additional, Sobieski, Mary, additional, Liu, Yuan, additional, Kim, Mark Seungwook, additional, Corvigno, Sara, additional, Foster, Katherine, additional, Hanjra, Pahul, additional, Vu, Thanh Chung, additional, Chowdhury, Mamur A., additional, Amero, Paola, additional, Stephan, Clifford, additional, Lopez-Berestein, Gabriel, additional, Westin, Shannon N., additional, and Sood, Anil K., additional

Published
2024
Full Text
View/download PDF

12. A-to-I-edited miRNA-379-5p inhibits cancer cell proliferation through CD97-induced apoptosis

Author

Xu, Xiaoyan, Wang, Yumeng, Mojumdar, Kamalika, Zhou, Zhicheng, Jeong, Kang Jin, Mangala, Lingegowda S., Yu, Shuangxing, Tsang, Yiu Huen, Rodriguez-Aguayo, Cristian, Lu, Yiling, Lopez-Berestein, Gabriel, Sood, Anil K., Mills, Gordon B., and Liang, Han

Subjects
Thermo Fisher Scientific Inc., Apoptosis, MicroRNA, Cancer -- Development and progression, Cancer research, Scientific equipment industry, Therapeutics, RNA, Tumors, Health care industry, University of Texas. M.D. Anderson Cancer Center
Abstract

Both miRNAs and A-to-I RNA editing, a widespread nucleotide modification mechanism, have recently emerged as key players in cancer pathophysiology. However, the functional impact of RNA editing of miRNAs in cancer remains largely unexplored. Here, we focused on an ADAR2-catalyzed RNA editing site within the miR-379-5p seed region. This site was under-edited in tumors relative to normal tissues, with a high editing level being correlated with better patient survival times across cancer types. We demonstrated that in contrast to wild-type miRNA, edited miR-379-5p inhibited cell proliferation and promoted apoptosis in diverse tumor contexts in vitro, which was due to the ability of edited but not wild-type miR-379-5p to target CD97. Importantly, through nanoliposomal delivery, edited miR-379-5p mimics significantly inhibited tumor growth and extended survival of mice. Our study indicates a role of RNA editing in diversifying miRNA function during cancer progression and highlights the translational potential of edited miRNAs as a new class of cancer therapeutics., Introduction Adenosine-to-inosine (A-to-I) RNA editing is a widespread posttranscriptional mechanism in humans that is catalyzed by adenosine deaminase acting on RNA (ADAR) enzymes and introduces specific nucleotide changes at the [...]

Published
2019
Full Text
View/download PDF

16. Author Correction: Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression

Author

Rupaimoole, Rajesha, Wu, Sherry Y., Pradeep, Sunila, Ivan, Cristina, Pecot, Chad V., Gharpure, Kshipra M., Nagaraja, Archana S., Armaiz-Pena, Guillermo N., McGuire, Michael, Zand, Behrouz, Dalton, Heather J., Filant, Justyna, Miller, Justin Bottsford, Lu, Chunhua, Sadaoui, Nouara C., Mangala, Lingegowda S., Taylor, Morgan, van den Beucken, Twan, Koch, Elizabeth, Rodriguez-Aguayo, Cristian, Huang, Li, Bar-Eli, Menashe, Wouters, Bradly G., Radovich, Milan, Ivan, Mircea, Calin, George A., Zhang, Wei, Lopez-Berestein, Gabriel, and Sood, Anil K.

Published
2020
Full Text
View/download PDF

17. Author Correction: Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

Author

Thaker, Premal H., Han, Liz Y., Kamat, Aparna A., Arevalo, Jesusa M., Takahashi, Rie, Lu, Chunhua, Jennings, Nicholas B., Armaiz-Pena, Guillermo, Bankson, James A., Ravoori, Murali, Merritt, William M., Lin, Yvonne G., Mangala, Lingegowda S., Kim, Tae Jin, Coleman, Robert L., Landen, Charles N., Li, Yang, Felix, Edward, Sanguino, Angela M., Newman, Robert A., Lloyd, Mary, Gershenson, David M., Kundra, Vikas, Lopez-Berestein, Gabriel, Lutgendorf, Susan K., Cole, Steven W., and Sood, Anil K.

Published
2021
Full Text
View/download PDF

18. Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance

Author

Leung, Cecilia S., Yeung, Tsz-Lun, Yip, Kay-Pong, Wong, Kwong-Kwok, Ho, Samuel Y., Mangala, Lingegowda S., Sood, Anil K., Lopez-Berestein, Gabriel, Sheng, Jianting, Wong, Stephen T.C., Birrer, Michael J., and Mok, Samuel C.

Subjects
Cell adhesion molecules -- Properties, Drug resistance -- Genetic aspects, Ovarian cancer -- Drug therapy, Fibroblasts -- Genetic aspects, Health care industry
Abstract

The molecular mechanism by which cancer-associated fibroblasts (CAFs) confer chemoresistance In ovarian cancer Is poorly understood. The purpose of the present study was to evaluate the roles of CAFs in modulating tumor vasculature, chemoresistance, and disease progression. Here, we found that CAFs upregulated the lipoma-preferred partner (LPP) gene in microvascular endothelial cells (MECs) and that LPP expression levels in intratumoral MECs correlated with survival and chemoresistance in patients with ovarian cancer. Mechanistically, LPP increased focal adhesion and stress fiber formation to promote endothelial cell motility and permeability. siRNA- mediated LPP silencing in ovarian tumor-bearing mice improved paclitaxel delivery to cancer cells by decreasing intratumoral microvessel leakiness. Further studies showed that CAFs regulate endothelial LPP via a calcium-dependent signaling pathway involving microfibrillar-associated protein 5 (MFAP5), focal adhesion kinase (FAK), ERK, and LPP. Thus, our findings suggest that targeting endothelial LPP enhances the efficacy of chemotherapy in ovarian cancer. Our data highlight the importance of CAF-endothelial cell crosstalk signaling in cancer chemoresistance and demonstrate the improved efficacy of using LPP-targeting siRNA in combination with cytotoxic drugs., Introduction High-grade serous ovarian cancer (HGSC) is the most common histological subtype of ovarian cancer and accounts for most ovarian cancer-related deaths. Most HGSCs are diagnosed at a late stage, [...]

Published
2018
Full Text
View/download PDF

20. Abstract 1463: Fxr1 is an oncogenic driver in ovarian cancer

Author

George, Jasmine, primary, Kadamberi, Ishaque P., additional, Geethadevi, Anjali, additional, Kumar, Sudhir, additional, Mittal, Sonam, additional, Rodriguez-Aguayo, Cristian, additional, Mangala, Lingegowda S., additional, Sood, Anil K., additional, Pradeep, Sunila, additional, and Chaluvally-Raghavan, Pradeep, additional

Published
2023
Full Text
View/download PDF

21. Abstract 2720: Enhancing oral delivery of plant-derived vesicles

Author

Liu, Yuan, primary, Lankenau-Ahumada, Adrian, additional, Bayraktar, Emine, additional, Schwartz, Paul, additional, Chowdhury, Mamur, additional, Shi, Sixiang, additional, Sebastian, Manu M., additional, Khant, Htet, additional, De Val, Natalia, additional, Jie, Zuliang, additional, Jennings, Nicholas B., additional, Rodriguez-Aguayo, Cristian, additional, Swain, Jody, additional, Stur, Elaine, additional, Mangala, Lingegowda S., additional, Wu, Yutuan, additional, Nagaraju, Supriya, additional, Erimas, Brooke, additional, Li, Chun, additional, Lopez-Berestein, Gabriel, additional, Braam, Janet, additional, and Sood, Anil K., additional

Published
2023
Full Text
View/download PDF

22. Supplementary Figure from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

Author

McGuire, Michael H., primary, Dasari, Santosh K., primary, Yao, Hui, primary, Wen, Yunfei, primary, Mangala, Lingegowda S., primary, Bayraktar, Emine, primary, Ma, Wencai, primary, Ivan, Cristina, primary, Shoshan, Einav, primary, Wu, Sherry Y., primary, Jonasch, Eric, primary, Bar-Eli, Menashe, primary, Wang, Jing, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

23. Data from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

Author

McGuire, Michael H., primary, Dasari, Santosh K., primary, Yao, Hui, primary, Wen, Yunfei, primary, Mangala, Lingegowda S., primary, Bayraktar, Emine, primary, Ma, Wencai, primary, Ivan, Cristina, primary, Shoshan, Einav, primary, Wu, Sherry Y., primary, Jonasch, Eric, primary, Bar-Eli, Menashe, primary, Wang, Jing, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

24. Data from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Author

Ma, Shaolin, primary, Pradeep, Sunila, primary, Villar-Prados, Alejandro, primary, Wen, Yunfei, primary, Bayraktar, Emine, primary, Mangala, Lingegowda S., primary, Kim, Mark Seungwook, primary, Wu, Sherry Y., primary, Hu, Wei, primary, Rodriguez-Aguayo, Cristian, primary, Leuschner, Carola, primary, Liang, Xiaoyan, primary, Ram, Prahlad T., primary, Schlacher, Katharina, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table S2 from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Author

Ma, Shaolin, primary, Pradeep, Sunila, primary, Villar-Prados, Alejandro, primary, Wen, Yunfei, primary, Bayraktar, Emine, primary, Mangala, Lingegowda S., primary, Kim, Mark Seungwook, primary, Wu, Sherry Y., primary, Hu, Wei, primary, Rodriguez-Aguayo, Cristian, primary, Leuschner, Carola, primary, Liang, Xiaoyan, primary, Ram, Prahlad T., primary, Schlacher, Katharina, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table from Gene Body Methylation of the Lymphocyte-Specific Gene CARD11 Results in Its Overexpression and Regulates Cancer mTOR Signaling

Author

McGuire, Michael H., primary, Dasari, Santosh K., primary, Yao, Hui, primary, Wen, Yunfei, primary, Mangala, Lingegowda S., primary, Bayraktar, Emine, primary, Ma, Wencai, primary, Ivan, Cristina, primary, Shoshan, Einav, primary, Wu, Sherry Y., primary, Jonasch, Eric, primary, Bar-Eli, Menashe, primary, Wang, Jing, primary, Baggerly, Keith A., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

27. Table S6 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figures from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Author

Huang, Yan, primary, Hu, Wei, primary, Huang, Jie, primary, Shen, Fangrong, primary, Sun, Yunjie, primary, Ivan, Cristina, primary, Pradeep, Sunila, primary, Dood, Robert, primary, Haemmerle, Monika, primary, Jiang, Dahai, primary, Mangala, Lingegowda S., primary, Noh, Kyunghee, primary, Hansen, Jean M., primary, Dalton, Heather J., primary, Previs, Rebecca A., primary, Nagaraja, Archana S., primary, McGuire, Michael, primary, Jennings, Nicholas B., primary, Broaddus, Russell, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

29. Data from Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Author

Huang, Yan, primary, Hu, Wei, primary, Huang, Jie, primary, Shen, Fangrong, primary, Sun, Yunjie, primary, Ivan, Cristina, primary, Pradeep, Sunila, primary, Dood, Robert, primary, Haemmerle, Monika, primary, Jiang, Dahai, primary, Mangala, Lingegowda S., primary, Noh, Kyunghee, primary, Hansen, Jean M., primary, Dalton, Heather J., primary, Previs, Rebecca A., primary, Nagaraja, Archana S., primary, McGuire, Michael, primary, Jennings, Nicholas B., primary, Broaddus, Russell, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

32. Table S1, Table S2, Table S3, Table S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

33. Supplementary materials and Supplementary Figures 1-9 from GnRH-R–Targeted Lytic Peptide Sensitizes BRCA Wild-type Ovarian Cancer to PARP Inhibition

Author

Ma, Shaolin, primary, Pradeep, Sunila, primary, Villar-Prados, Alejandro, primary, Wen, Yunfei, primary, Bayraktar, Emine, primary, Mangala, Lingegowda S., primary, Kim, Mark Seungwook, primary, Wu, Sherry Y., primary, Hu, Wei, primary, Rodriguez-Aguayo, Cristian, primary, Leuschner, Carola, primary, Liang, Xiaoyan, primary, Ram, Prahlad T., primary, Schlacher, Katharina, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

35. Data from Targeting c-MYC in Platinum-Resistant Ovarian Cancer

Author

Reyes-González, Jeyshka M., primary, Armaiz-Peña, Guillermo N., primary, Mangala, Lingegowda S., primary, Valiyeva, Fatma, primary, Ivan, Cristina, primary, Pradeep, Sunila, primary, Echevarría-Vargas, Ileabett M., primary, Rivera-Reyes, Adrian, primary, Sood, Anil K., primary, and Vivas-Mejía, Pablo E., primary

Published
2023
Full Text
View/download PDF

36. Figure S1, S2, S3, S4 and S5 from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

40. Data from PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer

Author

Hisamatsu, Takeshi, primary, McGuire, Michael, primary, Wu, Sherry Y., primary, Rupaimoole, Rajesha, primary, Pradeep, Sunila, primary, Bayraktar, Emine, primary, Noh, Kyunghee, primary, Hu, Wei, primary, Hansen, Jean M., primary, Lyons, Yasmin, primary, Gharpure, Kshipra M., primary, Nagaraja, Archana S., primary, Mangala, Lingegowda S., primary, Mitamura, Takashi, primary, Rodriguez-Aguayo, Cristian, primary, Eun, Young Gyu, primary, Rose, Johnathon, primary, Bartholomeusz, Geoffrey, primary, Ivan, Cristina, primary, Lee, Ju-Seog, primary, Matsuo, Koji, primary, Frumovitz, Michael, primary, Wong, Kwong K., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

41. Data from Targeted Gene Silencing Using RGD-Labeled Chitosan Nanoparticles

Author

Han, Hee Dong, primary, Mangala, Lingegowda S., primary, Lee, Jeong Won, primary, Shahzad, Mian M.K., primary, Kim, Hye Sun, primary, Shen, Deyu, primary, Nam, Eun Ji, primary, Mora, Edna M., primary, Stone, Rebecca L., primary, Lu, Chunhua, primary, Lee, Sun Joo, primary, Roh, Ju Won, primary, Nick, Alpa M., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

42. Figures S1-S6, Table S1-S3 from Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction

Author

Allen, Julie K., primary, Armaiz-Pena, Guillermo N., primary, Nagaraja, Archana S., primary, Sadaoui, Nouara C., primary, Ortiz, Tatiana, primary, Dood, Robert, primary, Ozcan, Merve, primary, Herder, Danielle M., primary, Haemmerle, Monika, primary, Gharpure, Kshipra M., primary, Rupaimoole, Rajesha, primary, Previs, Rebecca A., primary, Wu, Sherry Y., primary, Pradeep, Sunila, primary, Xu, Xiaoyun, primary, Han, Hee Dong, primary, Zand, Behrouz, primary, Dalton, Heather J., primary, Taylor, Morgan, primary, Hu, Wei, primary, Bottsford-Miller, Justin, primary, Moreno-Smith, Myrthala, primary, Kang, Yu, primary, Mangala, Lingegowda S., primary, Rodriguez-Aguayo, Cristian, primary, Sehgal, Vasudha, primary, Spaeth, Erika L., primary, Ram, Prahlad T., primary, Wong, Stephen T.C., primary, Marini, Frank C., primary, Lopez-Berestein, Gabriel, primary, Cole, Steve W., primary, Lutgendorf, Susan K., primary, De Biasi, Mariella, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

43. Supplementary data from Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability

Author

Yang, Hailing, primary, Mao, Weiqun, primary, Rodriguez-Aguayo, Cristian, primary, Mangala, Lingegowda S., primary, Bartholomeusz, Geoffrey, primary, Iles, Lakesla R., primary, Jennings, Nicholas B., primary, Ahmed, Ahmed Ashour, primary, Sood, Anil K., primary, Lopez-Berestein, Gabriel, primary, Lu, Zhen, primary, and Bast, Robert C., primary

Published
2023
Full Text
View/download PDF

44. Data from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer

Author

Wen, Yunfei, primary, Graybill, Whitney S., primary, Previs, Rebecca A., primary, Hu, Wei, primary, Ivan, Cristina, primary, Mangala, Lingegowda S., primary, Zand, Behrouz, primary, Nick, Alpa M., primary, Jennings, Nicholas B., primary, Dalton, Heather J., primary, Sehgal, Vasudha, primary, Ram, Prahlad, primary, Lee, Ju-Seog, primary, Vivas-Mejia, Pablo E., primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

45. Supplemental Table S5 from MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels

Author

Lu, Yunqi, primary, Hu, Zhongyi, primary, Mangala, Lingegowda S., primary, Stine, Zachary E., primary, Hu, Xiaowen, primary, Jiang, Dahai, primary, Xiang, Yan, primary, Zhang, Youyou, primary, Pradeep, Sunila, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, DeMarzo, Angelo M., primary, Sood, Anil K., primary, Zhang, Lin, primary, and Dang, Chi V., primary

Published
2023
Full Text
View/download PDF

46. Supplementary Data from EphA2 Targeted Chemotherapy Using an Antibody Drug Conjugate in Endometrial Carcinoma

Author

Lee, Jeong-Won, primary, Stone, Rebecca L., primary, Lee, Sun Joo, primary, Nam, Eun Ji, primary, Roh, Ju-Won, primary, Nick, Alpa M., primary, Han, Hee-Dong, primary, Shahzad, Mian M.K., primary, Kim, Hye-Sun, primary, Mangala, Lingegowda S., primary, Jennings, Nicholas B., primary, Mao, Shenlan, primary, Gooya, John, primary, Jackson, Dowdy, primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

47. Data from Functional Roles of Src and Fgr in Ovarian Carcinoma

Author

Kim, Hye-Sun, primary, Han, Hee Dong, primary, Armaiz-Pena, Guillermo N., primary, Stone, Rebecca L., primary, Nam, Eun Ji, primary, Lee, Jeong-Won, primary, Shahzad, Mian M. K., primary, Nick, Alpa M., primary, Lee, Sun Joo, primary, Roh, Ju-Won, primary, Nishimura, Masato, primary, Mangala, Lingegowda S., primary, Bottsford-Miller, Justin, primary, Gallick, Gary E., primary, Lopez-Berestein, Gabriel, primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

48. Data from Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth

Author

Lin, Yvonne G., primary, Immaneni, Anand, primary, Merritt, William M., primary, Mangala, Lingegowda S., primary, Kim, Seung Wook, primary, Shahzad, Mian M.K., primary, Tsang, Yvonne T.M., primary, Armaiz-Pena, Guillermo N., primary, Lu, Chunhua, primary, Kamat, Aparna A., primary, Han, Liz Y., primary, Spannuth, Whitney A., primary, Nick, Alpa M., primary, Landen, Charles N., primary, Wong, Kwong K., primary, Gray, Michael J., primary, Coleman, Robert L., primary, Bodurka, Diane C., primary, Brinkley, William R., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

49. Data from MYC Targeted Long Noncoding RNA DANCR Promotes Cancer in Part by Reducing p21 Levels

Author

Lu, Yunqi, primary, Hu, Zhongyi, primary, Mangala, Lingegowda S., primary, Stine, Zachary E., primary, Hu, Xiaowen, primary, Jiang, Dahai, primary, Xiang, Yan, primary, Zhang, Youyou, primary, Pradeep, Sunila, primary, Rodriguez-Aguayo, Cristian, primary, Lopez-Berestein, Gabriel, primary, DeMarzo, Angelo M., primary, Sood, Anil K., primary, Zhang, Lin, primary, and Dang, Chi V., primary

Published
2023
Full Text
View/download PDF

50. Supplementary Video 1 from Immunotherapy Targeting Folate Receptor Induces Cell Death Associated with Autophagy in Ovarian Cancer

Author

Wen, Yunfei, primary, Graybill, Whitney S., primary, Previs, Rebecca A., primary, Hu, Wei, primary, Ivan, Cristina, primary, Mangala, Lingegowda S., primary, Zand, Behrouz, primary, Nick, Alpa M., primary, Jennings, Nicholas B., primary, Dalton, Heather J., primary, Sehgal, Vasudha, primary, Ram, Prahlad, primary, Lee, Ju-Seog, primary, Vivas-Mejia, Pablo E., primary, Coleman, Robert L., primary, and Sood, Anil K., primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results